Doxorubicin Hydrochloride Liposome
40 interactions 3 explained in plain English
Medically reviewed by
Dr. Brian Staiger, PharmD, BCPS
· Updated Jul 4, 2026
· Editorial policy
· Data sources
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Most serious with:
Amitriptyline
Cyclophosphamide Injection
Cyclosporine Ophthalmic
Dexamethasone Ophthalmic
Clotrimazole
Clotrimazole Lozenge
Major
Doxorubicin Hydrochloride Liposome Amitriptyline Elavil Explained Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Doxorubicin Hydrochloride Liposome Sertraline Explained Increased CYP2D6 substrate exposure Details Doxorubicin Hydrochloride Liposome Abrocitinib Cibinqo Explained Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Doxorubicin Hydrochloride Liposome Azathioprine Azasan An increased risk of hepatotoxicity Details Doxorubicin Hydrochloride Liposome Azithromycin AzaSite Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Doxorubicin Hydrochloride Liposome Atorvastatin Atorvaliq Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Doxorubicin Hydrochloride Liposome Abiraterone Abirtega Increased DOXOrubicin exposure Details Doxorubicin Hydrochloride Liposome Alogliptin Nesina Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Doxorubicin Hydrochloride Liposome Canagliflozin Invokana Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Doxorubicin Hydrochloride Liposome Capmatinib Tabrecta Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Doxorubicin Hydrochloride Liposome Captopril Capoten® Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Doxorubicin Hydrochloride Liposome Cisplatin Injection Platinol-AQ® Leukemia Details Doxorubicin Hydrochloride Liposome Clotrimazole Aardora Anti-Fungal Maximum Strength Increased doxorubicin exposure and an increased risk of doxorubicin-related adverse reactions Details Doxorubicin Hydrochloride Liposome Clotrimazole Lozenge Mycelex® Increased doxorubicin exposure and an increased risk of doxorubicin-related adverse reactions Details Doxorubicin Hydrochloride Liposome Clotrimazole Topical Cruex Antifungal Increased doxorubicin exposure and an increased risk of doxorubicin-related adverse reactions Details Doxorubicin Hydrochloride Liposome Clotrimazole Vaginal Gyne-Lotrimin 3® Cream Increased doxorubicin exposure and an increased risk of doxorubicin-related adverse reactions Details Doxorubicin Hydrochloride Liposome Cyclophosphamide Cytoxan® Increased risk of cardiomyopathy Details Doxorubicin Hydrochloride Liposome Cyclophosphamide Injection Cytoxan® Injection Increased risk of cardiomyopathy Details Doxorubicin Hydrochloride Liposome Cyclosporine Injection Atopica Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Doxorubicin Hydrochloride Liposome Cyclosporine Ophthalmic Cequa Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Doxorubicin Hydrochloride Liposome Dexamethasone Injection Decadron Reduced DOXOrubicin exposure Details Doxorubicin Hydrochloride Liposome Dexamethasone Ophthalmic Dexacidin® (as a combination product containing Dexamethasone, Neomycin, Polymyxin B) Reduced DOXOrubicin exposure Details Doxorubicin Hydrochloride Liposome Elacestrant Orserdu Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Doxorubicin Hydrochloride Liposome Enasidenib Idhifa Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Doxorubicin Hydrochloride Liposome Entrectinib Rozlytrek Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Doxorubicin Hydrochloride Liposome Felodipine Plendil® Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Doxorubicin Hydrochloride Liposome Fostamatinib Tavalisse Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Doxorubicin Hydrochloride Liposome Ibrexafungerp Brexafemme Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Doxorubicin Hydrochloride Liposome Istradefylline Nourianz Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Doxorubicin Hydrochloride Liposome Ketoconazole Topical Extina® Foam Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Doxorubicin Hydrochloride Liposome Lenacapavir Injection Sunlenca Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Doxorubicin Hydrochloride Liposome Lenacapavir Oral Sunlenca Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Doxorubicin Hydrochloride Liposome Letermovir Injection Prevymis Increased doxorubicin exposure and an increased risk of doxorubicin-related adverse reactions Details Doxorubicin Hydrochloride Liposome Mercaptopurine Purinethol® An increased risk of hepatotoxicity Details Doxorubicin Hydrochloride Liposome Nafcillin Injection Unipen® Injection Reduced DOXOrubicin exposure Details Doxorubicin Hydrochloride Liposome Neratinib Nerlynx Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Doxorubicin Hydrochloride Liposome Nevirapine Viramune Reduced DOXOrubicin exposure Details Doxorubicin Hydrochloride Liposome Nifedipine Adalat® Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions DetailsMinor
Doxorubicin Hydrochloride Liposome Docetaxel Beizray Increase in DOXOrubicin exposure Details Doxorubicin Hydrochloride Liposome Docetaxel Injection Beizray Increase in DOXOrubicin exposure DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacistEducational information only, not medical advice. Always confirm interactions with your pharmacist
or prescriber before making any change to your medications.